Core Insights - VitalHub Corp. will release its financial results for Q3 2024 on November 13, 2024, after market close, followed by a conference call on November 14, 2024, at 9:00 am EST [1] - The company provides software solutions for Health and Human Services, aiming to enhance user experience and optimize outcomes for various healthcare providers [2] - VitalHub's growth strategy includes both organic growth within its product suite and an aggressive mergers and acquisitions (M&A) plan, serving over 1,000 clients globally [3][4] Company Overview - VitalHub is headquartered in Toronto, Canada, with an offshore development hub in Sri Lanka, employing over 500 team members worldwide [4] - The company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on the OTC Markets OTCQX Exchange under the symbol "VHIBF" [4] Product Offerings - The company offers a comprehensive suite of SaaS solutions, including Electronic Health Record (EHR), Case Management, Care Coordination, and Patient Flow Optimization [7]

TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Strata Health Solutions Inc. (“Strata Health”), a leading provider of patient flow solutions internationally. Based in Canada, Strata Health designs, builds, and deploys software that improves access and navigation to care. Strata Health has over 80 health system partners and works with over 500 hospitals to provide over 800,000 pat ...

● . . VitalHub Corp. Recognized Among Top Performers in the 2024 TSX30 Ranking September 10, 2024 7:31 AM EDT | Source: Toronto Stock Exchange Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is proud to announce its inclusion in the 2024 TSX30™, the Toronto Stock Exchange's prestigious ranking of the top 30 performing stocks over the past three years. VitalHub has achieved the 26th position on this esteemed list, showcasing a r ...

Financial Performance - Valhi reported net income attributable to stockholders of $19.9 million, or $0.70 per share, in Q2 2024, compared to a net loss of $3.2 million, or $0.11 per share, in Q2 2023[1]. - Total net sales for the three months ended June 30, 2024, were $559.7 million, compared to $507.1 million for the same period in 2023, representing a 10.5% increase[12]. - Basic and diluted net income per share for Q2 2024 was $0.70, compared to a loss of $0.11 per share in Q2 2023[12]. - Total operating income for the six months ended June 30, 2024, was $86.3 million, compared to $14.5 million for the same period in 2023[12]. Chemicals Segment Performance - The Chemicals Segment's net sales were $500.5 million in Q2 2024, an increase of $57.3 million, or 13%, compared to Q2 2023, driven by higher sales volumes of TiO2[2]. - Chemicals segment net sales increased from $443.2 million in Q2 2023 to $500.5 million in Q2 2024, a growth of 12.9%[12]. - TiO2 sales volumes increased by 29% in Q2 2024 compared to Q2 2023, and by 28% in the first six months of 2024 compared to the same period in 2023[2]. - Operating income for the chemicals segment improved significantly from a loss of $2.6 million in Q2 2023 to a profit of $40.5 million in Q2 2024[12]. - The Chemicals Segment's operating income was $40.5 million in Q2 2024, a significant improvement from an operating loss of $2.6 million in Q2 2023[3]. - The overall percentage change in TiO2 net sales was 13% for both the three and six months ended June 30, 2024, compared to 2023[13]. - The Chemicals Segment's production rates increased to 93% of practical capacity utilization in the first six months of 2024, up from 70% in the same period of 2023[3]. Other Segments Performance - The Component Products Segment's net sales decreased to $35.9 million in Q2 2024 from $36.6 million in Q2 2023, primarily due to lower marine components sales[5]. - The Real Estate Management and Development Segment reported sales of $23.3 million in Q2 2024, down from $27.3 million in Q2 2023, attributed to delays in obtaining city permits[6]. - The real estate management and development segment reported net sales of $23.3 million for Q2 2024, up from $27.3 million in Q2 2023, indicating a decrease of 14.7%[12]. Expenses and Financial Risks - Corporate expenses increased by 9% in Q2 2024 compared to Q2 2023, mainly due to higher environmental remediation costs[7]. - Interest expense rose by $4.7 million in Q2 2024 compared to Q2 2023, primarily due to higher interest rates following the Chemicals Segment's debt refinancing[7]. - Interest expense decreased from $11.9 million in Q2 2023 to $7.2 million in Q2 2024, reflecting a reduction of 39.5%[12]. - Valhi faces risks including fluctuations in raw material costs, changes in demand for products, and potential disruptions from global economic conditions[9].

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the "Company" or "VitalHub") is pleased to announce that it has signed a definitive agreement (the "Definitive Agreement") to acquire MedCurrent Corporation and its subsidiaries ("MedCurrent"), by way of a courtapproved plan of arrangement under the provisions of the Business Corporations Act (Ontario) (the "Transaction"). "This acquisition represents a significant step forward in our mission to enhance healthcare delivery ...

Core Insights - VitalHub Corp. will release its financial results for Q2 2024 on August 8, 2024, followed by a conference call on August 9, 2024, at 9:00 am EST [1] Company Overview - VitalHub is a leading software company focused on Health and Human Services, serving over 1,000 clients across multiple regions including Canada, USA, UK, Australia, the Middle East, and Europe [3][6] - The company offers a comprehensive suite of SaaS solutions, including Electronic Health Record (EHR), Case Management, Care Coordination, and Patient Flow Optimization [7] Growth Strategy - VitalHub employs a two-pronged growth strategy that includes targeting organic growth opportunities within its product suite and pursuing an aggressive M&A plan [3]

Financial Performance - Valhi reported net income attributable to stockholders of $7.8 million, or $0.27 per share, in Q1 2024, compared to a net loss of $4.9 million, or $0.17 per share, in Q1 2023[1] - Valhi's total net sales increased by $37.9 million (7.7%) to $530.6 million in Q1 2024, with total operating income rising to $31.5 million from $2.5 million in Q1 2023[15] - Valhi's income before taxes improved to $18.0 million in Q1 2024 from a loss of $9.8 million in Q1 2023, with net income attributable to stockholders increasing by $12.7 million[15] Chemicals Segment Performance - The Chemicals Segment's net sales increased by $52.5 million (12%) to $478.8 million in Q1 2024, driven by a 28% increase in TiO2 sales volumes and a $4 million positive impact from currency exchange rates[4][13] - The Chemicals Segment's operating income improved to $22.8 million in Q1 2024 from an operating loss of $15.1 million in Q1 2023, with TiO2 production volumes up 15% and capacity utilization increasing from 76% to 87%[10] - The Chemicals Segment's unabsorbed fixed costs decreased by $10 million to $12 million in Q1 2024 compared to $22 million in Q1 2023, reflecting improved production rates[10] - Average TiO2 selling prices were 11% lower in Q1 2024 compared to Q1 2023, with a 2% decline during the quarter[4] Component Products Segment Performance - The Component Products Segment's net sales decreased by $3.2 million (7.8%) to $38.0 million in Q1 2024, with operating income declining to $3.7 million from $7.0 million in Q1 2023[3] Real Estate Management and Development Segment Performance - The Real Estate Management and Development Segment's sales decreased by $11.4 million (45.2%) to $13.8 million in Q1 2024 due to reduced development activity[14] Interest Expense - Interest expense increased by $4.3 million in Q1 2024, primarily due to higher interest rates on the Chemicals Segment's refinanced debt and a $1.5 million charge for deferred financing costs write-off[11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Delaware 87-0110150 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-5467 V ...

VALHI REPORTS FOURTH QUARTER 2023 RESULTS DALLAS, TEXAS . . March 7, 2024. Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $3.9 million, or $.14 per share, in the fourth quarter of 2023 compared to a net loss of $9.4 million, or $.33 per share, in the fourth quarter of 2022. For the full year of 2023, Valhi reported a net loss attributable to Valhi stockholders of $12.1 million, or $.42 per share, compared to net income of $90.2 million, or $3.16 per share, for the full yea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-5467 VALHI, INC. (Exact name of Registrant as specified in its charter) Delaware 87-0110150 (State or other jurisdiction of Incorporation or organ ...